Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 2469-2473

  Spadaro, Alessandro ^a,b   Frotscher, Martin ^a   Hartmann, Rolf W ^a,c  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE 17; BENZOYL 6; ENZYME INHIBITOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIVER ENZYME; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOCRINE DISEASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; TUMOR CELL LINE;

ANIMALS; BENZOTHIAZOLES; CALLITHRIX; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; ESTRADIOL DEHYDROGENASES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MICROSOMES, LIVER; PLACENTA; PREGNANCY; RADIOLIGAND ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858032721     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201711b     Document Type: Article

References (37)

1. Sjoquist, K. M.; Martyn, J.; Edmondson, R. J.; Friedlander, M. L. The role of hormonal therapy in gynecological cancers-current status and future directions Int. J. Gynecol. Cancer 2011, 21, 1328-1333
2. Hartmann, R. W.; Frotscher, M.; Ledergerber, D.; Wächter, G. A.; Grün, G. L.; Sergejew, T. F. Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2 Arch. Pharm. (Weinheim, Ger.) 1996, 329, 251-261
3. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach J. Med. Chem. 2005, 48, 7282-7289
4. Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17alpha-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo J. Steroid Biochem. Mol. Biol. 2003, 84, 555-562
5. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
6. Lucas, S; Heim, R; Negri, M; Antes, I; Ries, C; Schewe, K. E.; Bisi, A; Gobbi, S; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
7. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
8. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
9. Lucas, S.; Negri, M.; Heim, R.; Zimmer, C.; Hartmann, R. W. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one derivatives J. Med. Chem. 2011, 54, 2307-2319
10. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First selective CYP11B1 inhibitors for the treatment of cortisol-dependent diseases ACS Med. Chem. Lett. 2011, 2, 2-6
11. Hille, U. E.; Zimmer, C.; Haupenthal, J.; Hartmann, R. W. Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases ACS Med. Chem. Lett. 2011, 2, 559-564
12. Picard, F.; Baston, E.; Reichert, W.; Hartmann, R. W. Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 2000, 8, 1479-1487
13. Marchais-Oberwinkler, S.; Henn, C.; Möller, G.; Klein, T.; Lordon, M.; Negri, M.; Oster, A.; Spadaro, A.; Werth, R.; Xu, K.; Frotscher, M.; Hartmann, R. W.; Adamski, J. 17β-Hydroxysteroid dehydrogenases (17β-HSD): novel therapeutic targets, protein structures and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 2011, 125, 66-82
14. Smuc, T.; Pucelj, M. R.; Sinkovec, J.; Husen, B.; Thole, H.; Lanisnik Rizner, T. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis Gynecol. Endocrinol. 2007, 23, 105-111
15. Kruchten, P.; Werth, R.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells J. Steroid Biochem. Mol. Biol. 2009, 114, 200-206
16. Husen, B.; Huhtinen, K.; Poutanen, M.; Kangas, L.; Messinger, J.; Thole, H. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme Mol. Cell. Endocrinol. 2006, 248, 109-113
17. Day, J. M.; Foster, P. A.; Tutill, H. J.; Parsons, M. F. C.; Newman, S. P.; Chander, S. K.; Allan, G. M.; Lawrence, H. R.; Vicker, N.; Potter, B. V. L; Reed, M. J.; Purohit, A. 17beta-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer Int. J. Cancer 2008, 122, 1931-1940
18. Möller, G.; Deluca, D.; Gege, C.; Rosinus, A.; Kowalik, D.; Peters, O.; Droescher, P.; Elger, W.; Adamski, J.; Hillisch, A. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and d -homo-estrone Bioorg. Med. Chem. 2009, 19, 6740-6744
19. Poirier, D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases Anti-Cancer Agents Med. Chem. 2009, 9, 642-660
20. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algül, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 2008, 16, 6423-6435
21. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity J. Med. Chem. 2009, 52, 6724-6743
22. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity Bioorg. Med. Chem. 2010, 18, 3494-3505
23. Oster, A.; Hinsberger, S.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2010, 53, 8176-8186
24. Allan, G. M.; Vicker, N.; Lawrence, H. R.; Tutill, H. J.; Day, J. M.; Huchet, M.; Ferrandis, E.; Reed, M. J.; Purohit, A.; Potter, B. V. L. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design Bioorg. Med. Chem. 2008, 16, 4438-4456
25. Lilienkampf, A.; Karkola, S.; Alho-Richmond, S.; Koskimies, P.; Johansson, N.; Huhtinen, K.; Vihko, K.; Wähälä, K. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3- d ]pyrimidin-4(3 H)-one core J. Med. Chem. 2009, 52, 6660-6671
26. Karkola, S.; Lilienkampf, A.; Wähälä, K. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3- d ]pyrimidin-4(3 H)-one core applying molecular dynamics simulations and ligand-protein docking ChemMedChem. 2008, 3, 461-472
27. Schuster, D.; Nashev, L. G.; Kirchmair, J.; Laggner, C.; Wolber, G.; Langer, T.; Odermatt, A. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries J. Med. Chem. 2008, 51, 4188-4199
28. Brozic, P.; Kocbek, P.; Sova, M.; Kristl, J.; Martens, S.; Adamski, J.; Gobec, S.; Lanisnik Rizner, T. Flavonoids and cinnamic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 2009, 301, 229-234
29. Starčević, S.; Brožič, P.; Turk, S.; Cesar, J.; Lanišnik Rižner, T.; Gobec, S. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2011, 54, 248-261
30. Starčević, S.; Turk, S.; Brus, B.; Cesar, J.; Lanišnik Rižner, T.; Gobec, S. Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening J. Steroid Biochem. Mol. Biol. 2011, 127, 255-261
31. Spadaro, A.; Negri, M.; Marchais-Oberwinkler, S.; Bey, E.; Frotscher, M. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) PLoS One 2012, 7, e29252
32. Einspanier, A.; Lieder, K.; Brüns, A.; Husen, B.; Thole, H.; Simon, C. Induction of endometriosis in the marmoset monkey (Callithrix jacchus) Mol. Hum. Reprod. 2006, 12, 291-299
33. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents Mol. Cell. Endocrinol. 2009, 301, 154-157
34. Klein, T.; Henn, C.; Negri, M.; Frotscher, M. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation PLoS One 2011, 6, e22990
35. Obase, H.; Tatsuno, H.; Goto, K.; Shigenobu, K.; Kasuya, Y.; Yamada, Y.; Fujii, K.; Yada, S. Synthesis and adrenergic β-blocking activity of some propanolamine derivatives Chem. Pharm. Bull. 1978, 26, 1443-1452
36. Davis, P. D. New Stilbenes with Vascular Damaging Activity. Int. Patent Appl. WO2001/012579A2, Feb 22, 2001.
37. Takashima, Y.; Kobayashi, Y. Synthesis of (S)-imperanene by using allylic substitution J. Org. Chem. 2009, 74, 5920-5926